Nanosonics Graduate Programs & Internships

What it does: An Australian infection prevention company that has successfully developed and commercialised a unique automated disinfection technology

Mission: To improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovating technologies that deliver improved standards of care.

Size and presence: About average for companies of similar size in the Australian market ($USD1.04M).

Best known for: The company strives to be a global leader in infection prevention innovation.

The good bits: Fast growing company and lots of opportunity to drive direction and implement change within the company.

The not so good bits: Some of the staff complains about a lot of politics and gossip in the office.

The Nanosonics story

Nanosonics is an Australian infection prevention company that has successfully developed and commercialised a unique automated disinfection technology, the trophon^® device, representing the first major innovation in high level disinfection for ultrasound probes in more than 20 years. The trophon device is fast becoming the global standard of care for ultrasound probe disinfection.

Preventable infections are exactly that - preventable. But many medical institutions are forced to spend time and resources dealing with outbreaks of preventable infections. These infections diminish a patient's quality of care and undermine a healthcare professional's capacity to provide this care.

For this reason Nanosonics constantly pursues breakthrough innovations with the potential to transform infection prevention. Our vision is to provide fail-safe infection prevention solutions that protect not only an institution's quality of care, but more importantly the lives of those they treat.

So we pioneer ground-breaking technologies to prevent life-altering infections. We set new standards that redefine best practice. And we strive to be a global leader in infection prevention innovation.

Culture & vibe

At Nanosonics, we constantly pursue breakthrough innovations with the potential to transform infection prevention. As we continue to grow, our employees experience new and varied opportunities right across the business. The Nanosonics workforce now represents over 29 different nationalities, with women representing 41% of employees. Joining the global team will see you working with colleagues who share the company’s "Infection Prevention. For Life." vision.

Recruitment process

• Recruitment activities will always involve a face-to-face interview with the Hiring Manager or People and Culture department during the recruitment process. No job offers will be made before this occurs.
• We will never engage in recruitment activities from any Gmail account (or other non Nanosonics domain).
• We will never request payment or provide payment of any funds during the recruitment process.

Career prospects

Whatever career you choose, you will find the work interesting, challenging and rewarding at Nanosonics.

Remuneration

The average salary for Nanosonics Ltd employees is $60000 per year.

Benefits

Leave & holidays
⛔ Bonus annual leave
✅ Bonus parental leave
✅ Unpaid extended leave

Finance & contract
✅ Permanent employee
✅ Signing bonus
✅ Annual bonus
⛔ Stock options

Flexible work
⛔ Full remote work
✅ Partial remote work
✅ Flexible working hours

Family & health
⛔ Child care
✅ Free gym
⛔ Pet friendly office
✅ Mental health days

Insurance
⛔ Hospital
⛔ Outpatient
⛔ Dental
⛔ Maternity

Perks
⛔ Free breakfast
⛔ Free lunch
✅ Free tea & coffee
✅ Free snacks
✅ Free dinner

Social Contributions

Nanosonics recognises that to achieve its corporate goals and objectives, we must seek simultaneously to understand and minimise our environmental impacts; meet our social responsibilities to our employees, customers and the broader community; and maintain high standards of corporate governance.

We have further developed our framework for ESG disclosure. We have undertaken our first materiality analysis to identify the environmental, social and governance topics which are most material for the Company and its key stakeholders. These will inform our business strategy and new product development priorities as well as guiding the content of this ESG report.

Our work has been guided by the leading frameworks for ESG disclosure which have been developed over the past decade. Nanosonics is proud to offer technology that protects over 70,000 patients every day from the risk of a healthcare associated infection from ultrasound procedures, reducing the burden on the healthcare system in the communities in which we operate.

Further, the adoption of Nanosonics’ technology means healthcare staff at thousands of customer sites are no longer exposed to the toxic chemicals previously used for ultrasound probe reprocessing. As our geographic footprint extends in North America, Europe, the Middle East and Asia Pacific, we are extending these benefits to more and more patients and healthcare staff.

Controversies

The COVID-19 pandemic saw Nanosonics share price drop 25 per cent in the first quarter of 2021 due to a ban on elective surgeries and drop off in demand for ultrasound cleaning devices.

In 2018 investors were cautioned about Nanosonics relying too much on only one customer, which had its own financial problems, as an outlet for its products.

In 2010 Nanosonics warned that it had become aware of a substandard component being used in the production of its Tryphon EPR ultrasound disinfectant device and had moved to rectify the problem.